Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
about
Cutaneous manifestations of hepatitis C in the era of new antiviral agentsChronic hepatitis C: future treatmentOral antiviral therapies for chronic hepatitis C infectionEffectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.Grade 4 febrile neutropenia and Fournier's Syndrome associated with triple therapy for hepatitis C virus: A case report.Antiviral drug allergy.Management of hepatitis C in patients with chronic kidney disease.Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis CPrediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin.Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis.Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials.Hepatitis C: management of side effects in the era of direct-acting antivirals.Treatment decisions and contemporary versus pending treatments for hepatitis C.Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.How to optimize current therapy of HCV genotype 1 infection with boceprevir.Safety of direct-acting antivirals in the treatment of chronic hepatitis C.An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials.Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents.Extrahepatic manifestations of HCV: the role of direct acting antivirals.Skin Adverse Events During Dual and Triple Therapy for HCV-Related CirrhosisHepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.Borderline tuberculoid leprosy and type 1 leprosy reaction in a hepatitis C patient during treatment with interferon and ribavirin.Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions.Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions.Low-Dose Cyclosporine A in the Treatment of Severe Atopic Dermatitis Complicated by Chronic Hepatitis C Virus Infection.Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1.Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhiCutaneous Eruption due to TelaprevirTelaprevir experience from Turkey.Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESSIncidence and Management of Rash in Telaprevir-Treated Patients.Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.Hepatitis C virus-associated pruritus: Etiopathogenesis and therapeutic strategies.[Hepatitis C virus: 25 years-old, the end?].Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment.Use of transcutaneous electrical nerve stimulation for chronic pruritus.[Undesired cutaneous adverse drug reactions: What is new?].Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan.Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus-related cirrhosis.
P2860
Q26773669-863A0221-0D79-48A0-BEF1-EE1DF0A20AFCQ26824075-B40BB558-7E5E-416B-B0A0-22790C4BEA70Q26830426-96B53959-F5AE-4A17-BDD6-F6A4F8198CE5Q33775903-F155439E-AAF2-49B5-8FD0-119B1167D6DDQ33845172-A6518829-19F8-4449-B09C-CA9BB1CF009BQ34075812-CE9473B3-1DD7-4B09-99E7-5CEE88B527D8Q34932338-B095AB1C-EA53-4C43-8A01-A6C1D3ED1BA1Q34987445-047EAF3E-F8D0-4B02-8F2E-74F3DB29E6EEQ35754227-91741A3A-2B00-4950-B5A5-A0C9F3374A01Q35839723-1CC11EA1-E8A8-4E45-B726-0AE02C913441Q37996076-7341BDAE-8731-494C-B2B2-EE07802DD803Q38034258-B7ED85D8-79A0-42C8-BBC3-09F7185F3898Q38069957-B3DAA153-6265-4903-BF8E-8BAA8804CE35Q38135774-8B63C9DC-DF6D-4399-B24C-B1DBC73B4DABQ38153794-B6C91A6E-9894-49ED-A61A-250B13E80614Q38174241-89E4FDA4-EB88-43DB-8242-898EE0697E77Q38189110-AA73E6E3-79C8-4FE5-AF25-39653C4FB609Q38244137-11AAF064-C89E-4568-A431-67AEFCC59E86Q38408888-C9C37C94-2F78-4F29-BC95-FE4C33D1D3E1Q38684508-7A5C9479-1A37-4F1F-B1E1-FFAE75D924E7Q38719719-EE075D31-B07A-4AB4-A49B-9DA4DC62E08EQ38933599-A86B75D4-0534-4C27-8DE5-6BAA1911E008Q39430045-01EB2193-CF04-41A7-B3BF-7A59443636C6Q40076404-C7A3B1A7-7D4F-4FCF-9163-4E65E20A44EEQ40191483-E64A62B8-4436-48CF-ADB3-DC517C469A0BQ40255636-0F931B37-3398-4831-92A9-4C556BFD77B2Q40707649-4C4924FD-825E-4FFF-8417-E54D309C0BBFQ40779106-D70D85D1-0C84-4F3B-95F2-7C39AD48C489Q41187000-CE358FA9-E3A7-44F5-ADCE-262225245B1AQ41194634-404E28BD-F9F1-4452-8E95-19B0DC865812Q42189040-2FED873D-F06C-42AA-915F-B7EBDEA9C2ECQ42211835-18DC65F7-152A-4F74-BBFA-4BBF7A415CC7Q42272479-71415136-83E0-4F8A-941C-C68DDC700CBDQ42323384-BA465E0E-66B0-48C7-AC08-84BD53EEF2C9Q44199367-04C4F512-6C48-42CA-A8AA-B2E417EAF00DQ45350709-C3D0F291-FAB2-45E8-A8E6-0DC317DAB165Q46617429-19856D2D-A8F7-4D1B-813C-AEF94A5C414FQ50059148-FBF6154F-1E48-4BDE-B07C-01F308CAACD8Q50548354-54C3FD9E-8DE4-4BFE-94DF-CD325056ED0FQ55069588-B12F6E3C-D613-440D-9AC3-036910B54E9F
P2860
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dermatological side effects of ...... a of direct-acting antivirals.
@en
Dermatological side effects of ...... a of direct-acting antivirals.
@nl
type
label
Dermatological side effects of ...... a of direct-acting antivirals.
@en
Dermatological side effects of ...... a of direct-acting antivirals.
@nl
prefLabel
Dermatological side effects of ...... a of direct-acting antivirals.
@en
Dermatological side effects of ...... a of direct-acting antivirals.
@nl
P2093
P50
P1476
Dermatological side effects of ...... a of direct-acting antivirals.
@en
P2093
Christophe Hézode
Geoffrey Dusheiko
Jann Lübbe
Jean-Claude Roujeau
Marc Bourlière
Nicolas Dupin
Odile Picard
Peter Buggisch
Ramon Pujol
P304
P356
10.1016/J.JHEP.2011.08.006
P577
2011-08-30T00:00:00Z